Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONITT: Onivyde, Talazoparib, Temozolomide in Recurrent Solid Malignancies and Ewing Sarcoma
NCT04901702Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jun 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of irinotecan liposome injection, talazoparib, temozolomide in solid tumor, Ewing sarcoma, sponsored by St. Jude Children's Research Hospital. Started Jun 2021; status: recruiting.
02
Drugs
irinotecan liposome injectiontalazoparibtemozolomide
03
Conditions
solid tumorEwing sarcoma
Beyond the preview
Go deeper on NCT04901702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901702.